Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population.
There were no new safety sign... Biopharmaceuticals, Oncology Eli Lilly, LARTRUVO, olaratumab, soft tissue sarcoma, leiomyosarcoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Leiomyosarcoma | Pharmaceuticals | Sarcomas | Soft Tissue Sarcoma | Study